Physician profile
Angela Bowman
NPI 1598028524
$1,437.44
in general payments reported to CMS, 2019-2025
19 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $188 · 2023: $297 · 2024: $816 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.04 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $229.13 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $219.57 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $140.92 | 2024 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $134.91 | 2023-2025 | |
| Astellas Pharma US INC | $130.26 | 2023-2024 | Veozah |
| Abbvie INC. | $111.97 | 2023-2025 | Ubrelvy |
| Amgen INC. | $101.18 | 2023-2025 | Evenity, Prolia, Repatha |
| Shield Therapeutics INC | $74.02 | 2024 | |
| Neurocrine Biosciences, INC. | $46.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.43 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $37.99 | 2022 | |
| Glaxosmithkline, LLC. | $33.53 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $26.85 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.61 | 2024 | Caplyta |
| Exact Sciences Corporation | $18.67 | 2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.71 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.86 | 2023 | Nuzyra |
| Ibsa Pharma INC. | $14.28 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $12.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.